Zusammenfassung
Der Vorteil der WHO-Klassifikation aus dem Jahr 2004 liegt in der weiteren Differenzierung der NZK-Subtypen. Sie orientiert sich nicht nur an histologischen oder immunhistochemischen Merkmalen, sondern bezieht auch die genetischen Unterschiede ein und erweitert hiermit die Diagnosemöglichkeiten.
Abstract
By integrating genetic data into the traditional histology and immunohistochemistry-based classification system, the revised WHO classification of malignant tumors (2004) defined additional renal cell carcinoma subtypes, thereby enabling the application of additional diagnostic procedures.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Argani P, Olgac S, Tickoo SK et al (2007) Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 31:1149–1160
Bardella C, El-Bahrawy M, Frizzell N et al (2011) Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol 225:4–11
Eble JN, Sauter G, Epstein JI et al (Hrsg) (2004) Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon
Hammerschmied CG, Walter B, Hartmann A (2008) Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options. Pathologe 29:354–363
Kim SH, Choi Y, Jeong HY et al (2011) Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma. Virchows Arch 459:299–306
Ljungberg B, Hanbury DC, Kuczyk MA et al (2007) Renal cell carcinoma guideline. Eur Urol 51:1502–1510
Martignoni G, Pea M, Gobbo S et al (2009) Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol 22:1016–1022
Nelson EC, Evans CP, Lara PN Jr (2007) Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 33:299–313
Ooi A, Wong JC, Petillo D et al (2011) An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20:511–523
Peruzzi B, Bottaro DP (2006) Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12:3657–3660
Rao Q, Williamson SR, Zhang S et al (2013) TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or Cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol 37:804–815
RKI (Hrsg) (2012) Krebs in Deutschland 2007/2008. Robert Koch Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V., Berlin
Sobin LH, Gospodarowicz MK, Wittekind C (Hrsg) (2009) TNM classification of malignant tumours. Wiley, Hoboken
Sugawara E, Togashi Y, Kuroda N et al (2012) Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 118:4427–4436
Sukov WR, Hodge JC, Lohse CM et al (2012) ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol 25:1516–1525
Interessenskonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dieser Beitrag ist eine überarbeitete und aktualisierte Version des Beitrags Pathologe 29:354–363 [4][4].
Rights and permissions
About this article
Cite this article
Stöhr, C., Amann, K. & Hartmann, A. Histopathologie des Nierenzellkarzinoms. Urologe 52, 942–948 (2013). https://doi.org/10.1007/s00120-013-3223-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-013-3223-4